Anti-Human CD3 x BCMA (Elranatamab)

This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Recombinant biosimilar antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Elranatamab. Clone RN613 (Elranatamab) is a bispecific antibody that targets B-cell maturation antigen (BCMA) and CD3 on T cells.

CD3 is an invariant antigen of the T cell TCR (T cell receptor)¹. BCMA is a member of the tumor necrosis factor family of receptors that regulates B cell maturation, proliferation, and survival by activating p38/NF-κB and inducing upregulation of antiapoptotic proteins². BCMA is highly expressed on multiple myeloma (MM) cells and is therefore a target of cancer immunotherapy.

Anti-Human CD3 x BCMA bispecific antibodies target both B-cell maturation antigen (BCMA) on plasma cells and CD3 on T-cells, inducing T-cell activation and cytotoxic activity against BCMA-expressing plasma cells.

Elranatamab (RN613), a bispecific antibody targeting BCMA and CD3 on T-cells, has shown potent T-cell-mediated anti-myeloma activity by bringing T-cells close to myeloma cells. Elranatamab is distributed in the body, with higher concentrations in blood and lymphatic tissues. In laboratory settings, Elranatamab is used to study the efficacy of bispecific antibodies in targeting multiple myeloma and to develop therapeutic strategies for relapsed or refractory multiple myeloma^3,4.

CD3ε is a T cell surface glycoprotein. BCMA is predominantly expressed on the surface of terminally differentiated B cells and is overexpressed and activated on malignant multiple myeloma B cells (plasmablasts and plasma cells).

CD3ε: TCR BCMA: TNFSF13B/BLyS/BAFF, TNFSF13/APRIL, TRAF1, TRAF2, TRAF3, TRAF5 and TRAF6

CD3ε: P07766
BCMA: Q02223

1. Mariuzza RA, Agnihotri P, Orban J. J Biol Chem. 295(4):914-925. 2020.
2. Pillarisetti K, Powers G, Luistro L, et al. Blood Adv. 4(18):4538-4549. 2020.
3. Bahlis NJ, Costello CL, Raje NS, et al. Nat Med. 2023;29(10):2570-2576.
4. Lesokhin AM, Tomasson MH, Arnulf B, et al. Nat Med. 2023;29(9):2259-2267.